Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2864)	6/1/2010 12:47:18 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

QCOR was up 8.65% and is still up 6.12% with volume of > 1.09M already > its ADV bigcharts.marketwatch.com An FDA advisory panel said Acthar was safe and effective as a treatment for infant spasms at a meeting on May 6. It is expected to have an FDA decision on June 11 <g> Acthar is QCOR's primary drug. It also markets Doral, for the treatment of insomnia. QCOR is among the rarest group, that has been able to make an all time H this month as it traded above the resistance at the $10 level and above its April 30 H <g> The 1stQ results (March) were good and the EE for 2010 & 2011 are around $0.60 & $0.75 vs. $0.40 in 2009 The ACTAY is $13.50 It seems that if it can get a thumbs up from the FDA on its Acthar and its present momentum, the stock could easily get to the $15 level.<g> bigcharts.marketwatch.com Bernard